Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition
Klaus P. Hoeflich, Mark A. Merchant, Christine Orr et al. · Cancer Research · 2011
Combinations of MAP/ERK kinase (MEK) and phosphoinositide 3-kinase (PI3K) inhibitors have shown promise in preclinical cancer models, leading to the initiation of clinical trials cotargeting these two key cancer signaling pathways. GDC-0973, a novel selective MEK inhibitor, and GDC-0941, a class I PI3K inhibitor, are in early stage clinical trials as both single agents and in combination. The discovery of these selective inhibitors has allowed investigation into the precise effects of combining inhibitors of two major signaling branches downstream of RAS. Here, we investigated multiple biomarkers in the mitogen-activated protein kinase (MAPK) and PI3K pathway to search for points of convergence that explain the increased apoptosis seen in combination. Using washout studies in vitro and alternate dosing schedules in mice, we showed that intermittent inhibition of the PI3K and MAPK pathway is sufficient for efficacy in BRAF and KRAS mutant cancer cells. The combination of GDC-0973 with the PI3K inhibitor GDC-0941 resulted in combination efficacy in vitro and in vivo via induction of biomarkers associated with apoptosis, including Bcl-2 family proapoptotic regulators. Therefore, these data suggest that continuous exposure of MEK and PI3K inhibitors in combination is not required for efficacy in preclinical cancer models and that sustained effects on downstream apoptosis biomarkers can be observed in response to intermittent dosing.
Cited by 241 works. doi:10.1158/0008-5472.can-11-1515
Authors
- Klaus P. Hoeflich
- Mark A. Merchant
- Christine Orr
- Jocelyn Chan
- Doug Den Otter
- Leanne Berry
- Ian M. Kasman
- Hartmut Koeppen
- Ken Rice
- Nai-Ying Yang
- Stefan Engst
- Stuart H. Johnston
- Lori S. Friedman
- Marcia P. Belvin
References
- Mutations of the BRAF gene in human cancer
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors
- AKT/PKB Signaling: Navigating Downstream
- BRAF mutation predicts sensitivity to MEK inhibition
- Targeting RAS signalling pathways in cancer therapy
- The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website
- Bim: a novel member of the Bcl‐2 family that promotes apoptosis
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- The PIK3CA gene is mutated with high frequency in human breast cancers
- Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer